Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Fabrizio Maggi and Daniele Focosi.
Fabrizio Maggi
Connection Strength
10.021
Daniele Focosi
  1. Molecular validation of pathogen-reduction technologies using rolling-circle amplification coupled with real-time PCR for torquetenovirus DNA quantification. Transfus Med. 2021 Oct; 31(5):371-376.
    View in: PubMed
    Score: 0.961
  2. Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19. Emerg Infect Dis. 2021 Oct; 27(10):2728-2731.
    View in: PubMed
    Score: 0.959
  3. SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses. 2021 06 23; 13(7).
    View in: PubMed
    Score: 0.952
  4. Is a single COVID-19 vaccine dose enough in convalescents ? Hum Vaccin Immunother. 2021 Sep 02; 17(9):2959-2961.
    View in: PubMed
    Score: 0.944
  5. Previous Humoral Immunity to the Endemic Seasonal Alphacoronaviruses NL63 and 229E Is Associated with Worse Clinical Outcome in COVID-19 and Suggests Original Antigenic Sin. Life (Basel). 2021 Apr 01; 11(4).
    View in: PubMed
    Score: 0.938
  6. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. 2021 11; 31(6):e2231.
    View in: PubMed
    Score: 0.935
  7. What is the optimal usage of coronavirus disease 2019 convalescent plasma donations? Clin Microbiol Infect. 2021 Feb; 27(2):163-165.
    View in: PubMed
    Score: 0.905
  8. Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. Emerg Microbes Infect. 2021 Dec; 10(1):710-712.
    View in: PubMed
    Score: 0.245
  9. Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution. Emerg Microbes Infect. 2021 Dec; 10(1):1254-1256.
    View in: PubMed
    Score: 0.245
  10. COVID-19 infodemics: the role of mainstream and social media. Clin Microbiol Infect. 2021 Nov; 27(11):1568-1569.
    View in: PubMed
    Score: 0.240
  11. Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy. J Med Virol. 2021 Dec; 93(12):6460-6461.
    View in: PubMed
    Score: 0.240
  12. SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients. J Med Virol. 2021 Sep; 93(9):5648-5649.
    View in: PubMed
    Score: 0.236
  13. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect. 2021 Jul; 27(7):987-992.
    View in: PubMed
    Score: 0.235
  14. Nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes. ERJ Open Res. 2021 Apr; 7(2).
    View in: PubMed
    Score: 0.235
  15. Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients. Vaccine. 2021 04 28; 39(18):2489-2490.
    View in: PubMed
    Score: 0.234
  16. Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy. Emerg Infect Dis. 2021 04; 27(4):1249-1251.
    View in: PubMed
    Score: 0.232
  17. Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs. Br J Clin Pharmacol. 2021 05; 87(5):2186-2188.
    View in: PubMed
    Score: 0.228
  18. Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy. Rev Med Virol. 2021 03; 31(2):e2170.
    View in: PubMed
    Score: 0.226
  19. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. 2020 Jan-Dec; 12(1):1854149.
    View in: PubMed
    Score: 0.215
  20. Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence. J Med Virol. 2022 02; 94(2):491-498.
    View in: PubMed
    Score: 0.205
  21. Low prevalence of Gemycircularvirus DNA in immunocompetent and immunocompromised subjects. New Microbiol. 2019 Apr; 42(2):118-120.
    View in: PubMed
    Score: 0.205
  22. Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. Viruses. 2021 07 31; 13(8).
    View in: PubMed
    Score: 0.060
  23. Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. Med Microbiol Immunol. 2019 Apr; 208(2):253-258.
    View in: PubMed
    Score: 0.051
  24. Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. J Med Virol. 2018 09; 90(9):1438-1443.
    View in: PubMed
    Score: 0.048
  25. Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients. J Clin Virol. 2017 09; 94:22-28.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.